GlassScriptPhysician profile
Emad Naem
NPI 1851357859
$5,717.45
in general payments reported to CMS, 2019-2025
42 companies · $2,592 in 2025
The $2,592 reported for 2025 was more than what 81% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $890 · 2024: $2,236 · 2025: $2,592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,717.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $747.35 | 2023-2025 | Omnipod |
| Novo Nordisk INC | $586.64 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Sanofi-Aventis U.S. LLC | $511.56 | 2023-2025 | |
| Amgen INC. | $376.99 | 2023-2025 | Evenity, Tepezza, Prolia |
| Mannkind Corporation | $305.30 | 2023-2024 | Afrezza |
| Lilly USA, LLC | $276.87 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $275.87 | 2023-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $215.96 | 2024-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $185.87 | 2023-2025 | |
| Beta Bionics, INC. | $182.39 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.91 | 2023-2025 | Jardiance |
| Tandem Diabetes Care, INC. | $148.37 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Radius Health, INC. | $138.71 | 2023-2025 | |
| Ascendis Pharma Endocrinology INC | $130.85 | 2024-2025 | Yorvipath |
| Cequr Corporation | $130.59 | 2024-2025 | Cequr Simplicity |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $128.65 | 2024-2025 | Xyosted |
| Corcept Therapeutics | $109.34 | 2023-2025 | Korlym |
| Medtronic, INC. | $109.14 | 2023-2025 | Minimed 780g, Inceptiv, Intellis Adaptivestim |
| Abbvie INC. | $107.79 | 2024-2025 | |
| Averitas Pharma INC. | $76.90 | 2024 | Qutenza |
| Ibsa Pharma INC. | $68.74 | 2024-2025 | Tirosint, Licart, Flector |
| Sequel Med Tech, LLC | $66.17 | 2025 | Twiist |
| Neurocrine Biosciences, INC. | $62.89 | 2025 | |
| Xeris Pharmaceuticals, INC. | $62.80 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Alexion Pharmaceuticals, INC. | $62.69 | 2024-2025 | Strensiq |
| Endo USA, INC. | $50.32 | 2025 | Xiaflex |
| Novartis Pharmaceuticals Corporation | $48.20 | 2023 | |
| Horizon Therapeutics Plc | $42.53 | 2023 | Tepezza |
| Astrazeneca Pharmaceuticals LP | $41.74 | 2023 | Farxiga |
| Astellas Pharma US INC | $39.64 | 2024-2025 | Veozah |
| Soleno Therapeutics, INC. | $35.17 | 2025 | Vykat Xr |
| Halozyme INC | $31.61 | 2023 | |
| Tolmar, INC. | $31.41 | 2025 | Jatenzo |
| Madrigal Pharmaceuticals | $24.18 | 2025 | Rezdiffra |
| Chiesi USA, INC. | $23.57 | 2025 | Mycapssa |
| Regeneron Healthcare Solutions, INC. | $22.56 | 2023 | Evkeeza |
| Pfizer INC. | $20.38 | 2024 | |
| Inspire Medical Systems, INC. | $19.37 | 2024 | Inspire |
| Recordati_rare_diseases_inc. | $18.85 | 2025 | Isturisa |
| Verity Pharmaceuticals INC. | $16.30 | 2025 | Tlando |
| Azurity Pharmaceuticals, INC. | $16.03 | 2023 | Horizant |
| Kyowa Kirin, INC. | $15.25 | 2024 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emad Naem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.